Clinical Trial Update: The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of SHR-1314 in pediatric patients aged 6 to less than 18 with moderate-to-severe plaque psoriasis; study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SHR-1314 (SHR-1314)

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | Phase 3 | Status: NOT_YET_RECRUITING